Pfizer Stock News

China has revised its pandemic guidelines to include Paxlovid oral COVID-19 therapy developed by Pfizer (PFE) as the country battles a resurgence in coronavirus cases.According to…

Pfizer Inc. (NYSE:PFE) makes and sells biopharma products. The hedge fund sentiment around the stock is overwhelmingly positive.

The World Health Organization said Wednesday the number of new COVID-19 cases reported globally rose in the week through March 13, breaking the streak of declining numbers seen since the end of Januar

AbbVie (ABBV) joins Scripps Research in the latter's SARS-CoV-2 research program to accelerate the development of new antiviral therapies for COVID-19.

Pfizer has asked the US Drug regulators to allow a second Covid-19 booster dose for people aged 65 and above, citing data from Israel''s study. The FDA may authorise Pfizer''s second booster dose by September.

Pfizer and BioNTech asked U.S. regulators on Tuesday to authorize an additional booster dose of their COVID-19 vaccine for seniors.

Compared with their rivals, these stocks look dirt cheap.

After a more than a year of deadlock, four leading members the World Trade Organization, the U.S., EU, India, and South Africa reached a consensus on Tuesday for key elements of…

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Little in biotech is working or controlling the pandemic for that matter, but the Biden Administrations Test-to-Treat initiative, announced at the State of the Union, places Todos Medical (OTCMKTS: TOMDF) in the pole position to capitalize on any iteration of pandemic going forward. TOMDF could even leapfrog big pharma giant Pfizer (NYSE: PFE ) which indicated its 3CL protease inhibitor Paxlovid was facing production constraints and is only expected to deliver 3.25 million doses in September. CEO of TOMDF Gerald Commissiong indicated in a Benzinga interview that there is “equivalent clinical activity between our compound and Pfizer’s“ and with respect to sales “it starts with a B not an M.” The company is almost totally derisked and assured a profitable path forward in testing or with the huge upside associated with a drug approval. The current market cap is $27 million and its trading pennies to the dollar.

Merck (MRK) decides to discontinue a late-stage prostate cancer study evaluating Keytruda in combination with AstraZeneca's Lynparza, following its failure to demonstrate a benefit in overall survival

Pfizer (PFE) and BioNTech (BNTX) believe that for individuals to be adequately protected, additional booster doses of COVID vaccines are needed.

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech File For Authorization Of Second Booster Dose Of COVID-19 Vaccine Pfizer, Inc. (NYSE: PFE ) and BioNTech SE (NASDAQ: BNTX ) said they have submitted an application to the U.S. Food and Drug Administration for the emergency use authorization of an additional booster dose for adults, 65 years of age and older, who have received an initial booster of any of the authorized or approved COVID-19 vaccines. Earlier this month, a CDC study found that the duo''s COVID-19 vaccine becomes less effective after four months following vaccination. Pfizer shares were up 0.73% at $52.59 in premarket trading and BioNTech shares were advancing 3.58% to $150.23. Iovance Gets FDA Approval to Commence Study Of TIL Therapy to Treat Lung Cancer Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) said the FDA has allowed an investigational new drug application to proceed with its first genetically modified tumor-infiltrating lymphocyte (TIL) therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage 3 or 4 non-small cell lung cancer.

Pfizer Inc (NYSE: PFE ) and BioNTech SE (NASDAQ: BNTX ) filed an application with the FDA seeking emergency use authorization for a second booster shot of their COVID-19 vaccine for people aged 65 and older. An analysis of data from over 1.1 million adults 60 years and older showed rates of confirmed infections were two times lower, and severe illness was four times lower in … Full story available on Benzinga.com

A jump in coronavirus rates measured at wastewater sampling sites monitored by the Centers for Disease Control and Prevention may be signaling a coming increase in COVID-19 cases in parts of the U.S.,